KYMR — Kymera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1815442 ·
Last close
$121.52
Market Cap
$10.37B
52W High
$142.92
52W Low
$62.91
ADV30
958,848
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -147,232,000 | -131,999,000 | 1,767,269,000 | 373,374,000 | 152,742,000 |
| Jun 2026 | 65,000,000 | — | -75,607,000 | -61,211,000 | 1,645,444,000 | 124,477,000 | 136,188,000 |
| Mar 2026 | 34,365,000 | — | -84,154,000 | -69,234,000 | 1,669,016,000 | 144,090,000 | 129,379,000 |
| Dec 2025 | 2,870,000 | — | -97,896,000 | -86,981,000 | 1,742,812,000 | 357,011,000 | 163,148,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-287,565,000
Investing CF
$-415,562,000
Financing CF
$963,973,000
CapEx
$-1,328,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.62
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,328,405,000
Inventory
—
Receivables
$20,000,000
ST Investments
$597,840,000
EBIT TTM
$-349,131,000
Pretax Income TTM
$-349,425,000
Interest Exp TTM
$294,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$102,235,000
EBITDA
$-398,483,008
Free Cash Flow
$-164,682,000
Enterprise Value
$9,915,965,440
Total Cash
$971,214,016
Total Debt
$76,599,000
Shares Out
85,371,397
Trailing EPS
$-3.64
Book Value
$18.92
ROE
-27.3%
ROA
-17.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 39,211,000 | -345,544,000 | -311,351,000 | 1,742,812,000 | 163,148,000 | 1,579,664,000 | -232,891,000 |
| Dec 2024 | 47,072,000 | -256,710,000 | -223,858,000 | 978,035,000 | 142,416,000 | 835,619,000 | -194,501,000 |
| Dec 2023 | 78,592,000 | -165,530,000 | -146,962,000 | 575,759,000 | 180,788,000 | 394,971,000 | -102,826,000 |
| Dec 2022 | 46,826,000 | -161,256,000 | -154,808,000 | 603,134,000 | 112,983,000 | 490,151,000 | -153,085,000 |
TTM Snapshot
Revenues TTM
$105,000,000
NetIncome TTM
$-299,601,000
OpCashFlow TTM
—
Assets (Latest)
$1,645,444,000
Forward EPS
$-5.04
Max Pain — expiry 2026-12-18
max pain strike: $110.00 · spot: $121.13 · call oi: 5,798 · put oi: 3,106
Expected Move to 2026-12-18:
±$59.65
(49.24%) —
implied range
$61.48 –
$180.78
· ATM straddle on $120.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGEN | REPLIGEN CORP | $10.30B | $162.18 | — |
| QGEN | QIAGEN N.V. | $10.27B | $49.75 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $10.94B | $95.97 | — |
| TECH | BIO-TECHNE Corp | $11.41B | $72.63 | — |
| PCVX | Vaxcyte, Inc. | $9.40B | $59.40 | — |
News headlines (Yahoo Finance, 1h cache)
Kymera Therapeutics (KYMR) Stock May Be Overvalued Following Positive KT 579 Data
2026-11-05 12:18 · Yahoo
Kymera Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-10-29 22:53 · Yahoo
Kymera (KYMR) Q3 2026 Earnings Call Transcript
2026-10-29 20:44 · Yahoo
Kymera Therapeutics Q3 Earnings Call Highlights
2026-10-29 18:14 · Yahoo
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
2026-10-28 20:01 · Yahoo
Kymera Therapeutics (KYMR) Nears Earnings With KT 621 In Focus, Is The Stock Still Cheap?
2026-10-27 22:16 · Yahoo
Could You Have Seen The Run In Kymera Stock Coming?
2026-10-26 21:34 · Yahoo
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
2026-10-22 20:01 · Yahoo
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
2026-10-19 13:08 · Yahoo
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.